Dicerna Pharmaceuticals Company Profile (NASDAQ:DRNA)

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals logoDicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: DRNA
  • CUSIP:
Key Metrics:
  • Previous Close: $2.91
  • 50 Day Moving Average: $2.80
  • 200 Day Moving Average: $3.38
  • 52-Week Range: $2.42 - $6.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.24
  • P/E Growth: 0.00
  • Market Cap: $60.39M
  • Outstanding Shares: 20,753,000
  • Beta: 2.24
Profitability:
  • Return on Equity: -85.11%
  • Return on Assets: -75.74%
Debt:
  • Current Ratio: 6.05%
  • Quick Ratio: 6.05%
Additional Links:
Companies Related to Dicerna Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Dicerna Pharmaceuticals (NASDAQ:DRNA) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $9.30 (219.59% upside)

Analysts' Ratings History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Show:
DateFirmActionRatingPrice TargetDetails
2/1/2017Leerink SwannReiterated RatingMkt PerformView Rating Details
12/12/2016HC WainwrightInitiated CoverageBuy$7.00View Rating Details
9/28/2016Stifel NicolausReiterated RatingBuy$13.00View Rating Details
8/15/2016Chardan CapitalLower Price TargetNeutral$4.00 -> $3.50View Rating Details
8/5/2016Cowen and CompanyReiterated RatingBuyView Rating Details
5/10/2016Jefferies Group LLCReiterated RatingBuy$19.00View Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
11/7/2016Q316($0.85)($0.68)$162.00 millionViewListenView Earnings Details
5/9/2016Q116($0.86)($0.76)ViewN/AView Earnings Details
3/10/2016Q415($0.84)($0.76)ViewListenView Earnings Details
11/10/2015Q315($0.84)($0.82)ViewListenView Earnings Details
8/6/2015Q215($0.78)($0.86)ViewN/AView Earnings Details
5/11/2015Q1($0.73)($0.79)$600.00 millionViewListenView Earnings Details
3/12/2015Q414($0.57)($0.57)$1.45 millionViewN/AView Earnings Details
11/6/2014($0.63)($0.63)ViewN/AView Earnings Details
8/7/2014($0.47)($0.64)ViewN/AView Earnings Details
5/13/2014Q114($0.52)($1.02)ViewN/AView Earnings Details
3/27/2014($0.62)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Current Year EPS Consensus Estimate: $-2.93 EPS
Next Year EPS Consensus Estimate: $-2.34 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20162($0.92)($0.85)($0.89)
Q3 20162($0.97)($0.94)($0.96)
Q4 20162($0.73)($0.70)($0.72)
Q1 20172($0.73)($0.59)($0.66)
Q2 20172($0.73)($0.60)($0.67)
Q3 20172($0.50)($0.34)($0.42)
Q4 20172($0.50)($0.34)($0.42)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Insider Ownership Percentage: 27.65%
Institutional Ownership Percentage: 58.56%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/16/2016Dennis LangerDirectorSell23,766$3.52$83,656.32View SEC Filing  
11/15/2016Douglas FambroughCEOBuy33,100$3.71$122,801.00View SEC Filing  
5/12/2016James B WeissmanInsiderBuy5,000$3.29$16,450.00View SEC Filing  
11/25/2014James E FlynnInsiderSell321,965$11.36$3,657,522.40View SEC Filing  
11/7/2014James E FlynnInsiderSell214,164$9.05$1,938,184.20View SEC Filing  
10/15/2014James E FlynnInsiderSell117,778$10.86$1,279,069.08View SEC Filing  
10/14/2014James E FlynnMajor ShareholderSell36,115$11.02$397,987.30View SEC Filing  
10/10/2014James E FlynnMajor ShareholderSell30,214$12.13$366,495.82View SEC Filing  
2/4/2014James E FlynnInsiderBuy1,000,000$15.00$15,000,000.00View SEC Filing  
2/4/2014Stephen J HoffmanDirectorBuy200,000$15.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Dicerna Pharmaceuticals (NASDAQ:DRNA)
DateHeadline
News IconDicerna Pharmaceuticals Inc DRNA Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:DRNA)
www.bioportfolio.com - February 18 at 9:13 AM
News IconA Keen Look At The Chart For Dicerna Pharmaceuticals, Inc. (DRNA) - NY Stock News (NASDAQ:DRNA)
nystocknews.com - February 17 at 7:00 PM
benzinga.com logoExclusive: Dicerna CEO Discusses Financials And Institutional Investors (NASDAQ:DRNA)
www.benzinga.com - February 16 at 8:09 PM
benzinga.com logoExclusive: Dicerna CEO Discusses Financials And Institutional Investors (NASDAQ:DRNA)
www.benzinga.com - February 16 at 8:09 PM
finance.yahoo.com logoDicerna Pharmaceuticals (DRNA) Rises: Stock Climbs 14% (NASDAQ:DRNA)
finance.yahoo.com - February 16 at 3:07 PM
News IconMicro-Cap Biotech Focus: Dicerna Pharmaceuticals Inc (DRNA) Presents Its Exciting New Drug Platform GalXC (NASDAQ:DRNA)
feedproxy.google.com - February 9 at 11:25 AM
finance.yahoo.com logoDicerna to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference (NASDAQ:DRNA)
finance.yahoo.com - February 8 at 5:18 PM
News IconInvestor Sphere: Keeping an Eye on Levels for Dicerna Pharmaceuticals Inc (DRNA) - Sherwood Daily (NASDAQ:DRNA)
sherwooddaily.com - February 3 at 3:19 AM
finance.yahoo.com logoDicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (NASDAQ:DRNA)
finance.yahoo.com - February 2 at 5:16 PM
marketexclusive.com logoAnalyst Activity – Leerink Swann Reiterates Mkt Perform on Dicerna Pharmaceuticals (NASDAQ:DRNA) (NASDAQ:DRNA)
marketexclusive.com - February 1 at 3:26 AM
News IconKeen Investors Taking a Look at Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Prospect Journal (NASDAQ:DRNA)
prospectjournal.com - January 31 at 3:35 AM
News IconAre Insiders Bumping Up Their Positions in Dicerna ... - Wall Street Beacon (NASDAQ:DRNA)
wsbeacon.com - January 31 at 3:35 AM
News IconIs This Stock Capable of a Bull Run: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Nelson Research (NASDAQ:DRNA)
nelsonobserver.com - January 30 at 5:40 PM
News IconEarnings According to Analysts for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)? - Aiken Advocate (NASDAQ:DRNA)
aikenadvocate.com - January 30 at 5:40 PM
News IconCalibrating the Trade: Watching Technicals on Shares of Dicerna Pharmaceuticals Inc (DRNA) - Sherwood Daily (NASDAQ:DRNA)
sherwooddaily.com - January 30 at 5:40 PM
News IconWhat's in Dicerna Pharmaceuticals Inc (DRNA) After Touching 52-Week Low? - The Randolph Guide (NASDAQ:DRNA)
randolphguide.com - January 30 at 5:40 PM
News IconAre Insiders Bumping Up Their Positions in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Wall Street Beacon (NASDAQ:DRNA)
wsbeacon.com - January 30 at 5:40 PM
News IconTrading Spotlight: Zooming in on Shares of Dicerna Pharmaceuticals Inc (DRNA) - Sherwood Daily (NASDAQ:DRNA)
sherwooddaily.com - January 27 at 4:10 AM
News IconSell-side is Weighing in on Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Earnings - Aiken Advocate (NASDAQ:DRNA)
aikenadvocate.com - January 27 at 4:10 AM
News IconDicerna Pharmaceuticals Inc (NASDAQ:DRNA) Valuation According ... - UK Market News (NASDAQ:DRNA)
www.ukmarketnews.co.uk - January 26 at 6:06 PM
investornewswire.com logoAnalyst Rating Of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA ... - Investor Newswire (NASDAQ:DRNA)
www.investornewswire.com - January 26 at 6:06 PM
News IconDicerna Pharmaceuticals Inc (NASDAQ:DRNA) Valuation According To Analysts (NASDAQ:DRNA)
prensariotiretail.com - January 25 at 5:58 PM
News IconTechnical Trading: Focus on Shares of Dicerna Pharmaceuticals Inc (DRNA) - Sherwood Daily (NASDAQ:DRNA)
sherwooddaily.com - January 24 at 3:10 AM
News IconAre Insiders Filling Their Own Pockets With Shares? Insider Update on Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Wall Street Beacon (NASDAQ:DRNA)
wsbeacon.com - January 24 at 3:10 AM
News IconPriming The Pump: Stock Volatility Spotted in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Wall Street Beacon (NASDAQ:DRNA)
wsbeacon.com - January 24 at 3:10 AM
News IconEarnings Take Center Stage; Analysts Weighing in on Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Aiken Advocate (NASDAQ:DRNA)
aikenadvocate.com - January 23 at 1:14 AM
News IconBargain or Bait? Stock Update on Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Prospect Journal (NASDAQ:DRNA)
prospectjournal.com - January 21 at 4:04 AM
News IconDicerna Pharmaceuticals Inc DRNA Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:DRNA)
www.bioportfolio.com - January 20 at 6:01 PM
News IconSell-side Taking Aim at Shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Aiken Advocate (NASDAQ:DRNA)
aikenadvocate.com - January 20 at 4:32 AM
News IconInvestors Priming the Pump as Stock Reaches Most Volatile List: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Wall Street Beacon (NASDAQ:DRNA)
wsbeacon.com - January 17 at 10:38 PM
News IconTop Rated Stock With Earnings Growth & Implied Upside: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Prospect Journal (NASDAQ:DRNA)
prospectjournal.com - January 17 at 8:15 AM
News IconTracking Corporate Insiders: What Are They Doing With Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Wall Street Beacon (NASDAQ:DRNA)
wsbeacon.com - January 17 at 8:15 AM
News IconWill The Needle Move For Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:DRNA)
wsbeacon.com - January 17 at 8:15 AM
us.rd.yahoo.com logoArray BioPharma (ARRY) Jumps: Stock Adds 7.5% in Session (NASDAQ:DRNA)
us.rd.yahoo.com - January 16 at 10:05 AM
News IconIs There a Spark Ahead for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Prospect Journal (NASDAQ:DRNA)
prospectjournal.com - January 12 at 5:16 PM
News IconMy Watchlist for Wednesday, January 11 (NASDAQ:DRNA)
ac-investor.blogspot.com - January 11 at 5:22 PM
News IconAnalysts Projecting Upside, Can This Stock Surge Higher: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Prospect Journal (NASDAQ:DRNA)
prospectjournal.com - January 9 at 9:46 PM
investornewswire.com logoDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Records An Impact Score Of 50 - Investor Newswire (NASDAQ:DRNA)
www.investornewswire.com - December 22 at 4:59 PM
News IconLooking at the Gauges on Dicerna Pharmaceuticals Inc (DRNA) - Yankee Analysts (NASDAQ:DRNA)
yankeeanalysts.com - December 21 at 10:23 AM
finance.yahoo.com logoCoverage initiated on Dicerna Pharmaceuticals by H.C. Wainwright (NASDAQ:DRNA)
finance.yahoo.com - December 12 at 12:02 PM
insidermonkey.com logoDo Hedge Funds Love Dicerna Pharmaceuticals Inc (DRNA)? (NASDAQ:DRNA)
www.insidermonkey.com - December 11 at 11:15 AM
News IconChart Inspection on Shares of Dicerna Pharmaceuticals Inc (DRNA) - Yankee Analysts (NASDAQ:DRNA)
yankeeanalysts.com - December 8 at 5:28 PM
News IconNew Analyst Ratings On Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) - NewsDen (NASDAQ:DRNA)
newsden.net - December 3 at 4:32 PM
News IconTraders are Following Technical Levels for Dicerna Pharmaceuticals Inc (DRNA) - Yankee Analysts (NASDAQ:DRNA)
yankeeanalysts.com - December 2 at 5:06 PM
News IconEarnings According to Analysts for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)? - CSZ News (NASDAQ:DRNA)
cincysportszone.com - November 25 at 9:54 AM
News IconTechnical Buzz on Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Wall Street Lion (NASDAQ:DRNA)
wslnews.com - November 22 at 4:23 PM
News IconTrading Radar: Zooming in on Shares of Dicerna Pharmaceuticals Inc (DRNA) - Yankee Analysts (NASDAQ:DRNA)
yankeeanalysts.com - November 22 at 4:23 PM
News IconChart Watch: Checking on Shares of Dicerna Pharmaceuticals Inc (DRNA) - Yankee Analysts (NASDAQ:DRNA)
yankeeanalysts.com - November 21 at 9:39 AM
News IconRelative Strength Index Check on Dicerna Pharmaceuticals Inc (DRNA) - MicroCap Wired (NASDAQ:DRNA)
www.microcapwired.com - November 18 at 9:41 PM
News IconWhat are the Levels Indicating for This Stock: Dicerna Pharmaceuticals Inc (DRNA) - Yankee Analysts (NASDAQ:DRNA)
yankeeanalysts.com - November 17 at 3:55 PM

Social

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Where is Dicerna Pharmaceuticals' stock going? Where will Dicerna Pharmaceuticals' stock price be in 2017?

5 brokers have issued 1 year target prices for Dicerna Pharmaceuticals' shares. Their forecasts range from $3.50 to $19.00. On average, they anticipate Dicerna Pharmaceuticals' share price to reach $9.30 in the next twelve months.

When will Dicerna Pharmaceuticals announce their earnings?

Dicerna Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

Who owns Dicerna Pharmaceuticals stock?

Dicerna Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (13.31%), RTW Investments LP (9.85%), Abingworth LLP (3.90%), Renaissance Technologies LLC (1.97%), Eventide Asset Management LLC (1.82%) and Palo Alto Investors LLC (0.76%). Company insiders that own Dicerna Pharmaceuticals stock include Dennis Langer, Douglas Fambrough and James B Weissman.

Who sold Dicerna Pharmaceuticals stock? Who is selling Dicerna Pharmaceuticals stock?

Dicerna Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LLC and FMR LLC.

Who bought Dicerna Pharmaceuticals stock? Who is buying Dicerna Pharmaceuticals stock?

Dicerna Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, RTW Investments LP and Dimensional Fund Advisors LP. Company insiders that have bought Dicerna Pharmaceuticals stock in the last two years include Douglas Fambrough and James B Weissman.

How do I buy Dicerna Pharmaceuticals stock?

Shares of Dicerna Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Dicerna Pharmaceuticals stock cost?

One share of Dicerna Pharmaceuticals stock can currently be purchased for approximately $2.91.

Dicerna Pharmaceuticals (NASDAQ:DRNA) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Earnings History Chart

Earnings by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Dividend History Chart

Dividend Payments by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Last Updated on 2/20/2017 by MarketBeat.com Staff